Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201207087 Principal Investigator: Ellis, Matthew
Title: A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated with Any Hormonal Therapy (FALCON)
Phase: III Disease Site: Breast, Female
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
This research study measures the size of breast cancer tumors every 12 weeks and will help decide whether fulvestrant slows the growth of these tumors more than anastrozole.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)